Fortunes in Big Pharma sometimes turn on a dime.
Last year, Merck was the darling of the industry, as sales of some new products grew at a healthy clip and the company turned the corner in litigation over Vioxx. Shareholders rewarded Merck handsomely, driving its share price up 33% in 2007, making it the second-best performer [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment